POSTER SESSION I Monday, February 28, 2005   —  9:30 AM - 12:00 Noon Convention Center, Exhibit Hall B BREAST PATHOLOGY 21 Remarkably High Frequency of EGFR Expression in Breast Carcinomas with Squamous Differentiation (110) V Bossuyt, O Fadare, M Martel, B Burtness, RL Camp, FA Tavassoli - School of Medicine, New Haven, CT 22 Is There a Ductal Carcinoma In Situ (DCIS) Counterpart to Invasive Basal-Like Breast Cancers? (112) BB Bryan, SJ Schnitt, LC Collins - Beth Israel Deaconess Medical Center; Harvard Medical School, Boston, MA 23 Separate Cavity Margin Samping at the Time of Initial Lumpectomy Significantly Reduces the Need for Re-Excision (115) D Cao, C Lin, S Woo, T Tsangaris, P Argani - The Johns Hopkins Hospital, Baltimore, MD 24 GATA-3 Expression Is a Predictor of Hormone Response in Breast Cancer Patients (121) V Ciocca, JP Palazzo, L Rose, C Daskalakis, P Parikh, R Weigel - Thomas Jefferson University, Philadelphia, PA 25 Prediction of Lymph Node Status Utilizing Selective Genomic Fluorescence In Situ Hybridization Markers in Invasive Breast Carcinoma (130) KS Doeden, T Bocklage, C Harris, L Davis, P Doherty, P Hraber, L Tang, B Hall, I Rabinowitz, T Williams, J Hozier - University of New Mexico, Albuquerque, NM; Exagen Diagnostics, Inc., Albuquerque, NM 26 Papillary Lesions of Breast: Value of CK5/6 in Defining Epithelial Proliferations (131) K Donev, U Raju - Henry Ford Hospital, Detroit, MI 27 Segregation of Mammographically Detected Calcifications in Stereotaxic Core Biopsies for Targeted Histologic Evaluation: Is It Necessary? (132) S Easley, FW Abdul-Karim, N Klein, N Wang - Case Western Reserve University, Cleveland, OH 28 Loss of Heterozygosity Patterns in Flat Atypical Lesions of the Breast (155) KV Inamdar, M Roemer, CA Abbud, I Newsham, UB Raju - Henry Ford Hospital, Detroit, MI 29 Prediction of Non-Sentinel Lymph Node Metastases in Sentinel Node Positive Invasive Breast Carcinomas (158) U Kapur, TC Rubinas, S Gabrum, JM Sinacore, PB Rajan, K Yao - Loyola University Medical Center, Maywood, IL 30 Diabetic Mastopathy in Patients with Non-Diabetic Autoimmune Disease (175) JE Love, TJ Lawton - University of Washington, Seattle, WA 31 Cellular Polarity in Ductal Carcinoma In Situ (185) SP Mehrotra, A Morimiya, B Agarwal, R Saxena, S Badve - Indiana University, Indianapolis, IN 32 Metaplastic (Sarcomatoid) Carcinomas of the Breast Lack the Abnormally Long Telomeres of the Pleomorphic Sarcomas That They Mimic Morphologically (219) T Sheridan, A Meeker, J Hicks, E Montgomery, A DeMarzo, P Argani - Johns Hopkins Hospital, Baltimore, MD 33 Significantly Improved Sensitivity for ER Detection in Breast Cancer Using a New Rabbit Monoclonal Anti-ER Antibody (SP1) (230) DO Treaba, AW Hing, CC Tse, LC Goldstein, TS Barry, P Kandalaft, CB Gilks, TO Nielsen, AM Gown - PhenoPath Laboratories and IMPRIS, Seattle, WA; University of British Columbia, Vancouver, BC, Canada 34 MDM2 as an Independent Prognostic Marker in Breast Carcinoma Patients (232) DA Turbin, MCU Cheang, K Gelmon, E Yorida, TO Nielsen, CB Gilks, DG Huntsman - Vancouver General Hospital and University of British Columbia, Vancouver, BC, Canada; British Columbia Cancer Agency, Vancouver, BC, Canada 35 Genomic Alterations in the Progression of Stage 2 Breast Carcinoma: An Array-Based Comparative Genomic Hybridization (A-CGH) Study (246) BJ Yoder, M Skacel, T Choueiri, DP Gaile, J Conroy, N Nowak, J Pettay, JP Crowe, RL Crownover, T Budd, RR Tubbs, DG Hicks - The Cleveland Clinic Foundation, Cleveland, OH; Roswell Park Cancer Institute, Buffalo, NY